Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

22 Oct 2010

Abstract excerpt

BACKGROUND: In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. DESIGN AND METHODS: We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Response and Inflammation
Share to Influenza Virus Research Studies
Share to Respiratory viral infections research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20971824
DOI: 10.3324/haematol.2010.032664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised hostPMID 20971824Read ↗

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patientsSemantic proximity Read ↗

Influenza Vaccination for Cancer Patients: An Algerian Single Center ExperienceSemantic proximity Read ↗

Antibody Responses to SARS-CoV-2 Infection in Cancer PatientsSemantic proximity Read ↗

A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 dosesSemantic proximity Read ↗

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer patients: Short ReviewSemantic proximity Read ↗

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Pandemic 2009 Influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study.Semantic proximity Read ↗

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

Vaccination of hematopoietic cell transplant recipientsSemantic proximity Read ↗

Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipientsSemantic proximity Read ↗

Influenza Vaccine Immunogenicity in Hemodialysis PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.